The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Open accessAbstract
The Dominantly Inherited Alzheimer Network (DIAN) is an international registry of individuals at risk for developing autosomal dominant Alzheimer's disease (AD). Its primary aims are to investigate the temporal ordering of AD pathophysiological changes that occur in asymptomatic mutation carriers and to identify those markers that herald the transition from cognitive normality to symptomatic AD. DIAN participants undergo longitudinal evaluations, including clinical and cognitive assessments and measurements of molecular and imaging AD biomarkers. This review details the unique attributes of DIAN as a model AD biomarker study and how it provides the infrastructure for innovative research projects, including clinical trials. The recent design and launch of the first anti-amyloid-beta secondary prevention trial in AD, led by the related DIAN Trials Unit, also are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DIAN participants are members of families carrying highly penetrant autosomal-dominant mutations in the genes encoding the amyloid beta precursor protein (APP) or presenilin 1 (PSEN1) or 2 (PSEN2)19.”
From Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) · cites this paper as [19]
In the citing paper
“Autosomal dominant AD (ADAD) is well suited to study biomarker trajectories due to the virtually complete penetrance of the mutations and consistency of symptom onset within families4,5.”
From Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“Even with the publication of the National Institute on Aging (NIA)-Alzheimer’s Association diagnostic criteria and guidelines for preclinical AD, mild cognitive impairment (MCI) due to AD, and symptomatic AD [33-35], many researchers and clinicians still consider the term preclinical AD to encompass prodromal AD, MCI,…”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationAlbert, M., DeKosky, S. T., Dickson, D. W., Dubois, B., Feldman, H., Fox, N. C., Gamst, A. C., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.96 · Cited by 2,643
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 1×
“AD pathology is present in the brain many years before the onset of clinical symptoms [5-11].”
BackgroundSelf-citationAlzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–142 of 142
McMillan, C. T., & Chételat, G. (2018) · Neurology · doi:10.1212/wnl.0000000000005362 · Cited by 11
Tailoring MAPK Pathways: New Therapeutic Avenues for Treating Alzheimer’s Disease
Sharma, A., Mehra, V., Kumar, V., Jain, A., & Prakash, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04919-0 · Cited by 10
Suicidal ideation is common in autosomal dominant Alzheimer's disease at‐risk persons
Ng, K. P., Richard‐Devantoy, S., Bertrand, J., Jiang, L., Pascoal, T. A., Mathotaarachchi, S. S., Therriault, J., Yatawara, C., Kandiah, N., Greenwood, C. M. T., et al. (2019) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5215 · Cited by 10
Kim, Y.-E., Cho, H., Kim, H. J., Na, D. L., Seo, S. W., & Ki, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-59829-z · Cited by 10
Alzheimer’s Disease Drug Development: A Research and Development Ecosystem
Cummings, J. L., Kinney, J. W., & Fillit, H. M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.002 · Cited by 10
Preclinical Alzheimer’s Disease: Implications for Refinement of the Concept
Vos, S. J. B., & Visser, P. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179943 · Cited by 12
Adiponectin Paradox as a Therapeutic Target in Alzheimer’s Disease
Waragai, M., Ho, G. J., Takamatsu, Y., Wada, R., Sugama, S., Takenouchi, T., Masliah, E., & Hashimoto, M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200416 · Cited by 10
Sekiyama, K., Takamatsu, Y., Koike, W., Waragai, M., Takenouchi, T., Sugama, S., & Hashimoto, M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151015 · Cited by 9
Graf, A., Risson, V., Gustavsson, A., Bezlyak, V., Caputo, A., Tariot, P. N., Langbaum, J. B. S., López, C. L., & Viglietta, V. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.49 · Cited by 9
Alzheimer's Disease Drug Development
(2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759 · Cited by 9
The Aged Dog as a Natural Model of Alzheimer’s Disease Progression
Araujo, J. A., Baulk, J., & de Rivera, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-53219-6_4 · Cited by 9
Wetmore, J. B., Rodriguez, S., Caro, D. D., Cabán, M., Uhlmann, W. R., Goldman, J. S., Leu, C., Godinez, J. D., Camarillo, I. A., Ferber, R. A., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70016 · Cited by 7
Beyond Alzheimer’s disease—translating biomarker insights across CNS diseases
Brady, L. S., Mahinrad, S., Edelmayer, R. M., Potter, W. Z., Hutten, S. J., Anticevic, A., Taylor‐Burds, C., Winston, C. N., Coetzee, T., Paulsen, J. S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adr2511 · Cited by 6
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
McCullough, A. A., Chen, C. D., Gordon, B. A., Joseph‐Mathurin, N., Jack, C. R., Koeppe, R., Hornbeck, R. C., Koudelis, D., McKay, N. S., Hobbs, D. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70347 · Cited by 6
Self-citationStructural biology of cell surface receptors implicated in Alzheimer’s disease
Hermans, S. J., Nero, T. L., Morton, C. J., Gooi, J. H., Crespi, G. A. N., Hancock, N. C., Gao, C., Ishii, K., Markulić, J., & Parker, M. W. (2021) · Biophysical Reviews · doi:10.1007/s12551-021-00903-9 · Cited by 6
Berres, M., Kukull, W. A., Miserez, A. R., Monsch, A. U., Monsell, S. E., & Spiegel, R. (2014) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2014.5 · Cited by 5
Unravelling Alzheimer's Disease: It's Not the Whole Story, but Aβ Still Matters
Buxbaum, J. N. (2019) · The FASEB Journal · doi:10.1096/fj.201901895 · Cited by 5
Tau protein as a target for Alzheimer’s disease management
Abdalla, A. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2015.01.017 · Cited by 5
Benefits and Risks of Add-On Therapies for Alzheimer’s Disease
Magierski, R., & Sobów, T. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.15.39 · Cited by 6
Cash, D. M., Morgan, K. E., O’Connor, A., Veale, T. D., Malone, I. B., Poole, T., Benzinger, T. L. S., Gordon, B. A., Ibáñez, L., Li, Y., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100133 · Cited by 4
Self-citationHerrmann, M. J., Wuttke, A., Breuninger, L., Eff, J., Ettlinger, S., Fischer, M., Götzelmann, A., Gram, A., Pomper, L. D., Schneider, E., et al. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02859-y · Cited by 4
Doering, S., McKay, N. S., Jana, N., Dombrowski, K., McCullough, A. A., Millar, P. R., Hobbs, D. A., Agrawal, R., Flores, S. E., Llibre‐Guerra, J. J., et al. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00405 · Cited by 4
Self-citationLiu, H., Li, J. C., Ziegemeier, E., Adams, S., McDade, E., Clifford, D. B., Cao, Y., Wang, G., Li, Y., Mills, S. L., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.61 · Cited by 4
Self-citationA promising new γ-secretase modulator for Alzheimer’s disease
Zakaria, J. A. D., & Vassar, R. J. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210077 · Cited by 4
UPDATE ON PREVENTION TRIALS IN ALZHEIMER’S DISEASE
Vellas, B. J. (2014) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2014.30 · Cited by 3
Dementia registries around the world: a review and recommendations
Krysinska, K. E., Sachdev, P. S., & Brodaty, H. (2016) · Cited by 2
Cortical asymmetry in autosomal dominant Alzheimer’s disease progression
Pérez‐Millan, A., Falgàs, N., Bosch, B., Borrego‐Écija, S., Antonell, A., Fernández‐Villullas, G., Esteller, D., Tort‐Merino, A., Bargalló, N., Balasa, M., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf488 · Cited by 1
Self-citationGroeneveld, J., Perlaza, D., Olivé, C., Grangeon, L., Tesi, N., Nicolas, A., Jiang, C., de Rojas, I., Wallon, D., Rousseau, S., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71738 · Cited by 1
Molecular Imaging and Precision Medicine in Dementia and Movement Disorders
Mallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · PET Clinics · doi:10.1016/j.cpet.2016.08.003 · Cited by 1
Krishnadas, P., & Smith, N. (2023) · doi:10.47120/npl.ms50 · Cited by 1
Recent Update of Clinical Drug Trials in Alzheimer’s Disease
Kang, H., & Park, K. W. (2015) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2015.4.2
Golde, T. E., Lessard, C. B., & Ran, Y. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00005-8
Investigating Amyloid β toxicity in Drosophila melanogaster
Jonson, M. (2017) · Linköping studies in science and technology. Dissertations · doi:10.3384/diss.diva-138389
Lessons Learned From Public Private Partnerships and Consortia: The ADNI Paradigm
Liu, E. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00017-5
Advantages and limitations of hiPSC-derived neurons for the study of neurodegeneration
Mishra, S., Deursen, C. V., Robert, A., van der Kant, R., & Young, J. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822277-5.00016-x
Boccalini, C., Dodich, A., Scheffler, M., Laganà, V., Fratto, E., Frisoni, G. B., Bruni, A. C., Colao, R., Perani, D., & Garibotto, V. (2024) · Neurology · doi:10.1212/wnl.0000000000210103
Katsumi, Y., Brickhouse, M. J., Hanford, L. C., Nielsen, J. A., Elliott, M. L., Mair, R. W., Touroutoglou, A., Eldaief, M. C., Buckner, R. L., & Dickerson, B. C. (2025) · medRxiv · doi:10.1101/2025.03.14.25323769
Katsumi, Y., Brickhouse, M. J., Hanford, L. C., Nielsen, J. A., Elliott, M. L., Mair, R. W., Touroutoglou, A., Eldaief, M. C., Buckner, R. L., & Dickerson, B. C. (2026) · Imaging Neuroscience · doi:10.1162/imag.a.1138
Vlegels, N., Robalo, B. M. D. B., Luca, A. D., van der Flier, W. M., Dominantly Inherited Alzheimer Network, Bateman, R. J., Benzinger, T. L. S., Cruchaga, C., Cash, D. M., Mori, H., et al. (2026) · medRxiv · doi:10.64898/2026.02.03.26345446
Self-citationLlibre‐Guerra, J. J., Lu, R., Clarens, M. F., Liu, I., Renton, A. E., Ryan, N. S., Goate, A., Aguillón, D., Allegri, R., Benzinger, T. L. S., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214804
Self-citationLate-Onset Alzheimer’s Disease: Search for Biomarkers, Risk Factors, and Management
Shirbhate, S., Warjukar, P., & Mishra, V. H. (2026) · International journal of Nutrition Pharmacology Neurological Diseases · doi:10.4103/ijnpnd.ijnpnd_129_24
Metadata
- Authors
- Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J
- Morris, John C
- Venue
- Alzheimer's Research & Therapy
- Published
- 2013
- Volume
- 5
- Issue
- 5
- Pages
- 48
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC3978584
- OpenAlex
- W2110630889
- Cited by
- 142
- References
- 44
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 10 · 2023: 6 · 2022: 8 · 2021: 10 · 2020: 12 · 2019: 14 · 2018: 9 · 2017: 12 · 2016: 21 · 2015: 16 · 2014: 11
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Alzheimer s Research & Therapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- National Institute on Aging (U19AG032438)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- autosomal dominant Alzheimer's disease, mutation carriers, Alzheimer's disease biomarkers, preclinical Alzheimer's disease, longitudinal assessment, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
